<unk>  is used to lower blood glucose levels in type 2 diabetes either alone or in combination with a sulfonylurea, metformin, or insulin. While<unk>  does decrease blood sugar levels, the main study that looked at the medication found no difference in the main cardiovascular outcomes that were looked at. The secondary outcome of death from all causes, myocardial infarction, and stroke were lower.<unk>  has been found to reduce all-cause mortality in type 2 diabetic patients compared to other therapies, with a 60% reduction in mortality in those exposed to<unk> , compared to those never exposed. Another study found an all-cause mortality hazard ratio of 0.33 for<unk>  after adjusting for >40 covariates, compared to insulin.
Pioglitazone
Rosiglitazone
Liraglutide
Linagliptin
Acarbose
Vildagliptin
Glibenclamide
Metformin